Galmed Pharmaceuticals annual r&d spending
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Galmed Pharmaceuticals R&D Spending Growth & History (GLMD)
Galmed Pharmaceuticals's r&d spending was $4.9M for fiscal 2025.
View full Galmed Pharmaceuticals company overviewGalmed Pharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.9M | $1.9M | +63.61% |
| 2024 | 2024-12-31 | $3.0M | −$590,000 | −16.53% |
| 2023 | 2023-12-31 | $3.6M | −$9.4M | −72.54% |
| 2022 | 2022-12-31 | $13.0M | −$14.2M | −52.26% |
| 2021 | 2021-12-31 | $27.2M | $1.1M | +4.36% |
| 2020 | 2020-12-31 | $26.1M | $7.9M | +43.47% |
| 2019 | 2019-12-31 | $18.2M | $9.9M | +118.69% |
| 2018 | 2018-12-31 | $8.3M | −$1.3M | −13.85% |
| 2017 | 2017-12-31 | $9.7M | −$4.6M | −32.38% |
| 2016 | 2016-12-31 | $14.3M | $6.6M | +87.06% |
| 2015 | 2015-12-31 | $7.6M | $965,000 | +14.48% |
| 2014 | 2014-12-31 | $6.7M | −$543,000 | −7.53% |
| 2013 | 2013-12-31 | $7.2M | $4.8M | +195.01% |
| 2012 | 2012-12-31 | $2.4M | — | — |
Galmed Pharmaceuticals quarterly r&d spending
Q2.15
Q2.16
Q2.17
Q2.18
Q2.19
Q2.20
Q2.21
Q2.22
Q2.23
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.8M | $724,000 | +68.43% |
| Q1 2026 | 2026-03-31 | $1.4M | $726,000 | +114.51% |
| Q4 2025 | 2025-12-31 | $2.1M | — | — |
| Q3 2025 | 2025-09-30 | $1.1M | $348,000 | +47.15% |
| Q2 2025 | 2025-06-30 | $1.1M | $524,000 | +98.13% |
| Q1 2025 | 2025-03-31 | $634,000 | — | — |
| Q3 2024 | 2024-09-30 | $738,000 | — | — |
| Q2 2024 | 2024-06-30 | $534,000 | −$275,000 | −33.99% |
| Q2 2023 | 2023-06-30 | $809,000 | −$1.8M | −68.64% |
| Q2 2022 | 2022-06-30 | $2.6M | −$4.5M | −63.33% |
| Q2 2021 | 2021-06-30 | $7.0M | $2.1M | +41.54% |
| Q2 2020 | 2020-06-30 | $5.0M | $1.5M | +42.27% |
| Q2 2019 | 2019-06-30 | $3.5M | $1.6M | +80.10% |
| Q2 2018 | 2018-06-30 | $1.9M | −$407,000 | −17.34% |
| Q2 2017 | 2017-06-30 | $2.3M | −$1.0M | −30.15% |
| Q2 2016 | 2016-06-30 | $3.4M | $1.8M | +115.11% |
| Q2 2015 | 2015-06-30 | $1.6M | — | — |
Galmed Pharmaceuticals r&d spending trends
Over the last five fiscal years, Galmed Pharmaceuticals's r&d spending decreased from $26.1M to $4.9M, a change of −$21.2M. The latest reported quarter, Q2 2026, shows $1.8M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Galmed Pharmaceuticals source filings ↗